Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Current Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Total Current Liabilities for 13 consecutive years, with $37.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 59.62% to $37.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $37.4 million, a 59.62% increase, with the full-year FY2024 number at $32.1 million, changed N/A from a year prior.
  • Total Current Liabilities was $37.4 million for Q3 2025 at Theravance Biopharma, down from $54.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $142.1 million in Q3 2022 to a low of $21.7 million in Q1 2024.
  • A 5-year average of $45.1 million and a median of $32.1 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: tumbled 82.15% in 2023, then skyrocketed 138.09% in 2025.
  • Theravance Biopharma's Total Current Liabilities stood at $66.1 million in 2021, then crashed by 56.55% to $28.7 million in 2022, then decreased by 11.66% to $25.4 million in 2023, then rose by 26.48% to $32.1 million in 2024, then grew by 16.59% to $37.4 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Total Current Liabilities are $37.4 million (Q3 2025), $54.6 million (Q2 2025), and $31.5 million (Q1 2025).